• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Celldex plans FDA filing for barzolvolimab in 2027; analysts cut price targets

FinanceInternationalTradingViewAI summary
Image: TradingView

Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027 and is enrolling patients in phase 3 trials for cold urticaria and symptomatic dermographism. Barclays kept its overweight rating on Celldex (CLDX) but cut its price target to $50 from $53. HC Wainwright reiterated its buy rating and lowered its target to $58 from $64, 107.4% above the Nov. 19 close of $27.96.

In 35 seconds

  • Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027.
  • The company is enrolling patients in phase 3 trials for cold urticaria and symptomatic dermographism.
  • Barclays keeps overweight but lowers its CLDX price target to $50 from $53.
Read the full story at TradingView

IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading